Floatz logo

Lotiglipron

Diabetes Mellitus

PfizerSmall moleculePhase 2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

43 Active assets in the Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Metformin
Erbil Polytechnic University
Phase 4A
Pioglitazone
Milton S. Hershey Medical Center
Phase 4BBB
Alogliptin
Takeda
Phase 3BBB
Glibenclamide
Takeda
Phase 4BBB
Acetylsalicylic Acid
Region Skane
Phase 4BBB

View all 50 →

Same molecule, other indications

Lotiglipron is also rated in:

obesity disorderDormant
CC
Indicative ·
42 / 100
View asset →
type 2 diabetes mellitusDormant
C
Indicative ·
39 / 100
View asset →
obesity disorderDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →